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Summary
 
We have analyzed the presentation of human histocompatability leukocyte antigen-A*0201–asso-
ciated tumor peptide antigen MAGE-3
 
271–279
 
 by melanoma cells. We show that specific cyto-
toxic T lymphocyte (CTL)-recognizing cells transfected with a minigene encoding the prepro-
cessed fragment MAGE-3
 
271–279
 
 failed to recognize cells expressing the full length MAGE-3
protein. Digestion of synthetic peptides extended at the NH
 
2
 
 or COOH terminus of MAGE-
3
 
271–279
 
 with purified human proteasome revealed that the generation of the COOH terminus
of the antigenic peptide was impaired. Surprisingly, addition of lactacystin to purified protea-
some, though partially inhibitory, resulted in the generation of the antigenic peptide. Further-
more, treatment of melanoma cells expressing the MAGE-3 protein with lactacystin resulted in
efficient lysis by MAGE-3
 
271–279
 
–specific CTL. We therefore postulate that the generation of
antigenic peptides by the proteasome in cells can be modulated by the selective inhibition of
certain of its enzymatic activities.
Key words: HLA class I molecule • antigen processing • melanoma cells • ubiquitin • mass 
spectrometry
 
T
 
he proteasome is a central, nonlysosomal protease lo-
calized in the nuclei and cytosol of eukaryotic cells. It
has been implicated in the catabolism of numerous intracel-
lular proteins, including transcription factors and regulatory
proteins as well as misfolded proteins (1–3). It is composed
of a 20S core onto which a cap, formed by at least 15 dif-
ferent protein subunits, associates in an ATP-dependent
manner, resulting in a 26S proteasome particle (4). The 26S
proteasome has been shown to degrade ubiquitylated pro-
tein substrates (3). A second cap, formed by the het-
erodimeric PA-28 
 
a
 
/
 
b
 
 (REG 
 
a
 
/
 
b
 
) has also been described
(5, 6). This cap increases the catalytic activity of the 20S
proteasome toward oligopeptides and, in certain cases,
modulates the cleavage activity of the proteasome, at least
in vitro (7). This form of the proteasome does not degrade
ubiquitylated substrates.
The 20S core proteasome is composed of 14 different sub-
units arranged in 4 heptameric rings denoted as 
 
a
 
7
 
b
 
7
 
b
 
7
 
a
 
7
 
(8, 9). The catalytic centers of the proteasome are localized
in the interior of the 
 
b
 
 subunits. Studies on the degradation
of short fluorogenic peptides by purified proteasome in
vitro have demonstrated the presence of at least five differ-
ent enzymatic activities: a tryptic-like activity, cleaving af-
ter basic residues; a chymotryptic-like activity, cleaving af-
ter hydrophobic amino acids; a peptidylglutamylpeptide
hydrolyzing (PGPH)
 
1
 
 activity, cleaving after acidic residues;
a “branched chain amino acid–preferring” (BrAAP) activity;
and a “small neutral amino acid–preferring” (SNAAP) activ-
ity (10).
The participation of the proteasome in the generation of
antigenic peptides presented by MHC class I molecules has
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been well documented (11–13). After their generation, an-
tigenic peptides are transported across the membrane of the
endoplasmic reticulum (ER) by the transporters associated
with antigen presentation (TAP). In the ER, newly synthe-
sized MHC class I heavy chain, 
 
b
 
2
 
-microglobulin, and
peptide form a trimolecular complex that is then trans-
ported to the cell surface (14). Purification and biochemical
characterization of peptides naturally associated with de-
fined MHC class I alleles led to the discovery that these
peptides are of relatively homogenous length (8–10 amino
acids) and carry conserved amino acid residues at certain
positions. These residues, defined as anchor residues, were
shown to form direct contacts with the MHC molecule.
Based on this information, the prediction of putative anti-
genic peptides for defined MHC class I proteins has be-
come possible.
 
MAGE-3
 
 belongs to the human 
 
MAGE
 
 multigene fam-
ily, is characterized by its tumor-restricted expression, and
gives rise to several antigenic peptides presented by differ-
ent MHC class I molecules (15–17). MAGE-3 antigenic
peptides have therefore become attractive candidates for
the study of antitumor responses by CTL. In an attempt to
identify antigenic peptides, a series of 9-mer peptide se-
quences derived from the MAGE-3 protein and carrying
anchor residues for HLA-A*0201 were chemically synthe-
sized and tested for binding to HLA-A*0201. Among the
MAGE-3–derived peptides binding to HLA-A*0201, one
peptide, MAGE-3
 
271–279
 
, was able to induce a specific CTL
response in vitro when added to a culture of PBL from an
HLA-A*0201
 
1
 
 healthy individual (17). Subsequently, pep-
tide MAGE-3
 
271–279
 
 was used to derive specific CTL using
PBL from melanoma patients (18). Surprisingly, these CTL
were able to lyse HLA-A*0201
 
1
 
 melanoma cells pulsed
with exogenous peptides but were unable to recognize
melanoma cells expressing the MAGE-3 protein endoge-
nously. To elucidate this discrepancy, we have investigated
the processing of the MAGE-3 gene product.
Here we show that the lack of presentation of peptide
MAGE-3
 
271–279
 
 by HLA-A*0201
 
1
 
 cells is caused by the
inaccurate cleavage of the MAGE-3 protein during its
processing. Cells were tested for recognition by MAGE-
3
 
271–279
 
–specific CTL following intracellular expression of a
minigene-encoded MAGE-3
 
271–279
 
 peptide extended either
at the NH
 
2
 
 or COOH terminus. In contrast to cells ex-
pressing the NH
 
2
 
-terminally extended peptide precursor,
cells expressing the COOH-terminally extended peptide
precursor were not recognized by specific CTL. Mass spec-
trometry analysis of the corresponding synthetic peptide
precursors incubated with purified human proteasome
demonstrated that the antigenic peptide could be generated
from the NH
 
2
 
-terminally extended precursor but not from
the COOH-terminally extended precursor. Surprisingly,
addition of a specific proteasome inhibitor, lactacystin, re-
stored the generation of the antigenic peptide from the
COOH-terminally extended precursor. Analysis of the en-
zymatic activity of the proteasome in the presence of the
proteasome inhibitor supported this discrepancy. Finally,
treatment of HLA-A*0201
 
1
 
 melanoma cells expressing
 
MAGE-3 with lactacystin or another proteasome inhibitor,
 
N
 
-acetyl-Leu-Leu-norleucinal (LLnL), restored the presen-
tation of MAGE-3
 
271–279
 
. Implication of these findings on
the modulatory effect of proteasome inhibitor on the gen-
eration of peptides presented by HLA class I is discussed.
 
Materials and Methods
 
Cell Lines.
 
The human melanoma cell lines NA8-MEL (pro-
vided by Dr. F. Jotereau, Institut National de la Santé et de la Re-
cherche Médicale, Nantes, France) and SK23-MEL were cultured
in RPMI medium (GIBCO BRL) supplemented with 10% FCS,
antibiotics, and 20 mM NaHepes (pH 7.3). The CTL line LAU
198 NS (normal stimulation) specific for peptide MAGE-3
 
271–279
 
was established by stimulating CD8
 
1
 
-enriched cells from a LAU
198 melanoma patient with peptide-pulsed, autologous PBL as de-
scribed (18). The CTL line was restimulated weekly with irradiated
(3,000 rads) autologous PBL. Before irradiation, PBL were incu-
bated for 2 h at 37
 
8
 
C in serum-free medium (X-VIVO 10; Bio-
Whittaker) in the presence of the synthetic peptide MAGE-3
 
271–279
 
(1 
 
m
 
g/ml) and 3 
 
m
 
g/ml human 
 
b
 
2
 
-microglobulin (Sigma Chemical
Co.) and then washed extensively to remove unattached peptide.
The CTL clone 3C5 used in Fig. 7 was isolated as described previ-
ously (19). In brief, PBL were stained with tetramers of HLA-
A*0201–
 
b
 
2
 
-microglobulin containing the peptide MAGE-3
 
271–279
 
.
After cell sorting by FACS
 
®
 
 (Becton Dickinson), positive cells
were cloned in the presence of irradiated PBL, 5 
 
m
 
g/ml PHA,
and 50 U/ml IL-2 in human serum containing IMDM. The hu-
man lymphoblastoid cell lines T2 and LCL721.45 were used as
targets in 
 
51
 
Cr release assay. These cells were cultured in DMEM
(GIBCO BRL) supplemented with 10% FCS, 0.55 mM arginine,
0.24 mM asparagine, and 1.5 mM glutamine. The TNF-
 
a
 
–sensi-
tive cell line WEHI-164 clone 13 was maintained in RPMI me-
dium (GIBCO BRL) supplemented with 10% FCS, 0.55 mM
arginine, 0.24 mM asparagine, and 1.5 mM glutamine.
 
Construction of Plasmids and Ubiquitin/Protein/Reference (UPR)
Technique.
 
All plasmid constructs described in this study were
based on the plasmid pS65T-C1 (Clontech). This vector carries,
under the control of the cytomegalovirus immediate early promoter,
a mutated version of the green fluorescence protein (GFP), result-
ing in brighter fluorescence. The stop codon of the GFP moiety
has been replaced by a multicloning site allowing COOH-terminal
fusions to GFP. A fragment encoding yeast ubiquitin (Ub) carry-
ing a lysine
 
48
 
 to arginine mutation (to preclude that the COOH-
terminal Ub moiety could serve as a ubiquitylation/degradation
signal) and an influenza hemagglutinin epitope (ha) recognized by
a monoclonal antibody was obtained by PCR, using the plasmid
pRc/dUb–Met–
 
b
 
gal as template (20). This PCR fragment was
digested with KpnI and SmaI and inserted in frame between the
KpnI and SmaI sites present in the multicloning site of pS65T-
C1, resulting in the vector pGFP
 
AvaI
 
/Ub expressing the fusion
GFP–ha–Ub. The ha epitope is located between the GFP and Ub
moieties. The plasmid pGFP
 
AvaI
 
/Ub was further digested with
XhoI and EcoRI, blunted using Klenow PolI, and religated,
thereby eliminating the AvaI site between GFP and Ub and ren-
dering the site AvaI at the 3
 
9
 
 end of Ub unique. This latter con-
struct, termed pGFP/Ub, served as vector for all constructs de-
scribed below.
Construct I (Fig. 1) was obtained by PCR amplification of a
fragment encoding the tumor antigen MAGE-3 (a gift from T.
Boon, Ludwig Institute for Cancer Research, Brussels, Belgium).
This PCR fragment was digested with SacII and AvaI and in-
serted in frame between the SacII and AvaI sites of pGFP/Ub, re-
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sulting in the plasmid pGFP/Ub–MAGE-3
 
1–314
 
. The protein
MAGE-3 includes the natural NH
 
2
 
-terminal methionine. Con-
structs II, III, and IV were obtained by annealing complementary
synthetic oligonucleotides encoding the MAGE-3–derived pep-
tide fragments MAGE-3
 
271–279
 
, MAGE-3
 
256–279
 
, and MAGE-3
 
271–285
 
,
respectively. The oligonucleotides were designed so as to recon-
stitute the SacII site at the 5
 
9
 
 end and the AvaI site at the 3
 
9
 
 end
of the fragment and included a stop codon immediately upstream
of the AvaI site. Upon annealing, the fragments were inserted be-
tween the SacII–AvaI sites of pGFP/Ub, resulting in the plasmids
pGFP/Ub–MAGE-3
 
271–279
 
 (Fig. 1, construct II), pGFP/Ub–
MAGE-3
 
256–279
 
 (construct III), and pGFP/Ub–MAGE-3
 
271–285
 
(construct IV). The sequences of the critical regions of all con-
structs were confirmed by DNA sequencing.
 
Transfection and Metabolic Labeling.
 
Cells were transiently trans-
fected using the Lipofectamine reagent (GIBCO BRL) according
to the manufacturer’s protocol. For metabolic labeling, 3 
 
3
 
 10
 
6
 
cells were transfected with 4 
 
m
 
g plasmid DNA. After 8 h, an
equal volume of DMEM containing 10% FCS was added to the
cells. After a further 12-h incubation at 37
 
8
 
C, the culture me-
dium was replaced with 1 ml DMEM lacking methionine and
 
cysteine (ICN Biomedicals, Inc.), and the cells were incubated
for 1 h at 37
 
8
 
C. Cells were labeled for 90 min at 37
 
8
 
C in the
presence of 200 
 
m
 
Ci of [
 
35
 
S]Express (New England Nuclear).
The cells were then lysed in 1 ml lysis buffer (1% Triton X-100,
0.15 M NaCl, 5 mM EDTA, 20 mM Tris–HCl [pH 7.3], and 0.2
mg/ml phenylmethylsulfonyl fluoride) and maintained on ice.
The lysate was cleared by centrifugation at 12,000 
 
g
 
 for 10 min.
The volumes of supernatant were adjusted to contain equal amount
of 10% TCA-insoluble, 
 
35
 
S-labeled material and immunoprecipi-
tated using a mixture of a saturating amount of a monoclonal anti-
body anti-ha epitope (Berkeley Antibody Co.) and a monoclonal
antibody against MAGE-3 (21; a gift from G. Spagnoli, University
of Basel, Basel, Switzerland). The samples were incubated with
rotary shaking at 4
 
8
 
C for 30 min, followed by the addition of 20
 
m
 
l protein G–Sepharose and another 30-min incubation at 4
 
8
 
C.
The immunoprecipitate was washed three times in lysis buffer
containing 0.1% SDS, resuspended in 20 
 
m
 
l SDS–sample buffer
(100 mM Tris–HCl, pH 8.8; 1.2 M sucrose; 0.01% bromophenol
blue; 2% SDS; and 90 mM dithiothreitol), and boiled at 100
 
8
 
C
for 3 min. The samples were subjected to SDS–12% PAGE fol-
lowed by autoradiography.
 
TNF-
 
a
 
 Release Assay.
 
Cells were transfected using the same
protocol as for the metabolic labeling with the following modifi-
cations: 10
 
4
 
 cells were transfected in 96-well, round bottom mi-
crotiter plates with 200 ng plasmid DNA and 1 
 
m
 
l Lipofectamine
in a final volume of 100 
 
m
 
l DMEM. After 6 h at 37
 
8
 
C, 100 
 
m
 
l
DMEM containing 10% FCS was added to each well, and the
cells were maintained at 37
 
8
 
C for another 14 h. At this point, the
transfected cells were tested for their ability to stimulate the re-
lease of TNF-
 
a
 
 by the MAGE-3
 
271–279
 
–specific CTL line. In
brief, CTLs were added at the appropriate effector-to-target cell
ratio (E/T) in 100 
 
m
 
l of IMDM supplemented with 10% human
serum and 20 U/ml human rIL-2 (Glaxo Wellcome) provided by
Dr. M. Nabholz (Swiss Institute for Experimental Cancer Re-
search, Epalinges, Switzerland). After a 24-h incubation at 37
 
8
 
C,
supernatants were collected and the TNF-
 
a
 
 content was deter-
mined in a functional assay using WEHI-164 clone 13 cells (22)
as described (23).
 
Proteasome Purification.
 
Proteasome was purified from human
outdated blood by affinity chromatography using the monoclonal
antibody MCP 21 (European Collection of Animal Cell Cultures)
immobilized on CnBr-activated Sepharose (6 mg antibody/mg
Sepharose; 24). 
 
z
 
150 ml blood was washed five times with cold
PBS, and the cells were pelleted at 2,000 
 
g
 
 for 10 min. This pellet
was resuspended in 1/5 volume of sterile H
 
2
 
O and mechanically dis-
rupted by douncing in a Dounce homogenator. Immediately after
this treatment, sucrose was added to the homogenate to a final con-
centration of 250 mM. Unsolubilized material was removed by cen-
trifugation. Cleared lysate was incubated for 3 h at 4
 
8
 
C under rotary
shaking with the immobilized mAb MCP 21 as a batch preparation.
The material was then loaded onto a column and washed extensively
with 20 mM Tris–HCl (pH 7.6), and 50 mM NaCl to remove unat-
tached material. 20S proteasome was eluted with 20 mM Tris–HCl
(pH 7.6) and 2 M NaCl. The eluate was dialysed for 24 h at 4
 
8
 
C
against 20 mM Tris–HCl (pH 7.6) and concentrated to 4 mg/ml.
The average yield was 
 
z
 
1 mg purified proteasome/150 ml blood.
Homogeneity of the eluted material was confirmed by analysis of an
aliquot by SDS–12% PAGE and Coomassie blue staining of the gel.
 
Enzymatic Assays.
 
The activity of the proteasome was assayed
using the following fluorogenic peptides: Z–Gly–Gly–Arg–
 
b
 
NA
(Z–GGR–
 
bNA; Z 5 benzyloxycarbonyl and bNA 5 b-naph-
tylamide) for tryptic-like activity, Z–Leu–Leu–Glu–bNA (Z–LLE–
bNA) for PGPH activity, and Suc–Leu–Leu–Val–Tyr–AMC
Figure 1. (A) UPR constructs. The plasmid pGFP/Ub–MAGE-31–314
encodes a tripartite fusion protein in which ubiquitin (Ub) is sandwiched
between the reference protein GFPha and the full length protein MAGE-3
(construct I). During or shortly after the translation of this fusion, the GFP-
ha–Ub moiety is cleaved at the last residue of Ub by a Ub-specific pro-
tease, resulting in equimolar amounts of the reference protein GFPha–Ub
and the protein MAGE-3. The plasmid pGFP/Ub–MAGE-3271–279 (con-
struct II) encodes the reference protein GFPha–Ub and a fragment of
MAGE-3 corresponding to the antigenic peptide associated with HLA-
A*0201. The plasmid pGFP/Ub–MAGE-3256–279 (construct III) encodes
the reference protein GFPha–Ub and a fragment of MAGE-3 corre-
sponding to a 15–amino acid NH2-terminal extension of the antigenic
peptide MAGE-3271–279. The plasmid pGFP/Ub–MAGE-3271–285 (con-
struct IV) encodes the reference protein GFPha–Ub and a fragment of
MAGE-3 corresponding to a six-amino acid COOH-terminal extension
of MAGE-3271–279. The residue methionine at the NH2 terminus of the
protein GFP results from the translation of the initiation codon ATG.
The term ha denotes a peptide sequence derived from the influenza hem-
agglutinin that is recognized by a specific antibody. The segment corre-
sponding to the antigenic peptide in each construct is indicated as a white
box. (B) Synthetic peptides corresponding to the NH2-terminal (MAGE-
3256–279) and the COOH-terminal (MAGE-3271–285) extensions of the an-
tigenic 9-mer are described in one-letter code together with their molec-
ular masses in daltons (Da). The antigenic peptide sequence is boxed.
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(Suc–LLVY–AMC; Suc 5 succinyl, and AMC 5 7-amido-4-
methylcoumarin) for chymotryptic-like activity. All peptides were
purchased from Bachem. Each degradation assay contained 5 mg
proteasome plus 100 mM peptides Z–GGR–bNA and Z–LLE–
bNA or 10 mM Suc–LLVY–AMC in a final volume of 100 ml.
The reaction was incubated at 258C for 20 min, at which time
the reaction was quenched with cold 100% ethanol. Fluorescence
emission was measured using a Perkin Elmer fluorometer. Fluo-
rescence excitation/emission wavelengths were 335:410 nm for
bNA and 380:440 nm for AMC. Where indicated, the protea-
some inhibitor lactacystin (Biomol) was incubated for 15 min
with proteasome at 258C before the addition of the peptide sub-
strates. The final concentration of lactacystin was 50 mM.
Peptide Synthesis. Peptides were synthesized using standard
solid-phase F-moc chemistry on an Applied Biosystems synthe-
sizer. After side chain deprotection and release from the resin, the
peptides were purified by reverse-phase preparative HPLC using
a Vydac C18 column. Fractions containing the expected product,
as judged by mass spectrometry, were pooled and lyophilized.
The purified material was then subjected to matrix assisted laser
desorption ionization-time of flight (MALDI-TOF) and analyti-
cal HPLC analysis. All peptides were .95% pure as indicated by
analytical HPLC.
Peptide Digestion and Mass Spectrometry. For analysis by mass
spectrometry, 4 nmol peptide was incubated for 40 min at 378C
with 16 mg purified proteasome in a final volume of 10 ml.
Where indicated, lactacystin was added to a final concentration of
50 mM. The samples containing proteasome and lactacystin were
incubated for 15 min at 378C before the addition of peptide. The
reaction was terminated by the addition of 5% TFA and immedi-
ate immersion in liquid N2. The samples were subsequently lyoph-
ilized. The lyophilized samples were dissolved in 20 ml 1% TFA/
H2O. An aliquot of this solution (1.5 ml) was mixed with 24 ml
of matrix solution (5 mg/ml a-cyano-4-hydroxyl-cinnamic acid;
Sigma Chemical Co.) in 1% TFA/H2O:acetonitrile (1:1, vol/vol)
and 1 ml of this mixture was deposited on a gold plated target and
vacuum dried before transferring it into the source of the mass
spectrometer.
MALDI mass spectra were obtained on a Perseptive Biosys-
tems Voyager RP spectrometer using a 337-nm nitrogen laser, a
25-kV accelerating potential, and a delayed extraction of 150 ns.
Each spectrum was the result of an accumulation of 128 single la-
ser shots. External calibration of the MALDI spectra in the linear
mode was carried out using a low molecular weight standard
(Perseptive Biosystems). The mass determination was based on
the mass-to-charge (m/z) ratio. The instrument error ranges be-
tween 0.01 and 0.1% of the molecular mass.
Peptide Digestion and 51Cr Release Assay. Samples used in sub-
sequent CTL assay included 100 pmol peptide and 4 mg purified
proteasome. Where indicated, trypsin (1 mg/ml) was added to
the peptide and incubated for 20 min at 378C in 10 mM Tris–
HCl, pH 8.0. The reaction performed was identical to the reac-
tion for the mass spectrometry analysis. Target cells were labeled
with 51Cr for 1 h at 378C and washed twice. Labeled target cells
(1,000 cells in 50 ml RPMI medium/5% FCS) were added to
serial dilutions of the various peptide preparations (100 ml) in
v-bottomed microwells for 15 min at room temperature. The
CTL were then added at the appropriate E/T in 50 ml RPMI
medium/5% FCS, and the release of 51Cr was measured after in-
cubation for 4 h at 378C. Specific lysis was calculated as follows:
% specific lysis Experimental release spontaneous release–( )
Total release spontaneous release–( )
⁄[
] 100.·
=
Infection with Recombinant Vaccinia Virus and Treatment of Cells
with Proteasome Inhibitors. Approximately 106 LCL721.45 cells
(25) were treated with 100 mM lactacystin for 1 h, washed, and
incubated overnight in 1 mM lactacystin at 378C. Cells were then
infected with recombinant vaccinia virus (rec. v.v.) expressing
the MAGE-31–314 protein at a multiplicity of infection of 10 and
simultaneously labeled with 100 mCi of 51Cr for 2 h. The cells
were washed and incubated at 378C for another 4 h before being
exposed to the MAGE-3–specific CTL clone 3C5 at the E/T in-
dicated in Fig. 7. Rec. v.v. encoding the MAGE-3 protein was
generated by recombination with a pSc11 derivative plasmid as
described previously (26). The cDNA coding for MAGE-3 was
digested with PstI and XbaI, blunted using Klenow PolI, and in-
serted into the SmaI site of the vector pSc11.
The HLA-A*02011 MAGE-31 melanoma cell line SK23-
MEL (18) was treated with 10 mM lactacystin or 100 mM LLnL
for 17 h. Subsequently, 106 cells were labeled with 100 mCi of
51Cr for 2 h, washed, and incubated with the MAGE-3–specific
CTL clone 3C5 for 8 h at 378C.
Results
Experimental Strategy. We have previously derived a
MAGE-3271–279–specific CTL line from PBL of a mela-
noma patient that, although able to readily recognize HLA-
A*02011 cells exposed to exogenously added synthetic
MAGE-3271–279 peptide, was unable to lyse cells expressing
the MAGE-3 protein (18). To address this discrepancy, we
assessed in the present study the recognition of HLA-
A*02011 melanoma cells transfected with cDNA or cDNA
fragments encoding the MAGE-3 protein. Expression of
the various MAGE-3 gene products in transfected cells was
determined by the UPR technique, originally developed to
increase the accuracy of protein decay measurements (20).
Ub is a highly conserved protein that, in many instances,
serves as a proteasomal degradation signal by forming a
multiubiquitin chain on lysine residue(s) of a protein (27).
Ub is naturally synthesized as a fused protein—either to it-
self or to other cellular proteins—and is rapidly cleaved by a
member of the Ub-specific proteases. The UPR technique
exploits this natural linear arrangement of the Ub gene and
relies on a linear fusion with Ub located between a refer-
ence protein (here GFP) and a protein of interest (Fig. 1).
The rapid cleavage of the fusion protein by Ub-specific
proteases after the last residue of Ub yields equimolar
amounts of the protein of interest and the reference protein
bearing a COOH-terminal Ub moiety. It is noteworthy
that the use of Ub fusion also enabled us to bypass the need
for a methionine residue at the NH2 termini of the
MAGE-3 peptide fragments. Finally, a sequence encoding
a peptide tag derived from the influenza ha was inserted be-
tween the GFP and Ub moieties to permit the detection
and quantitation of GFPha–Ub fusion.
NA8-MEL cells (HLA-A*02011MAGE-32) were tran-
siently transfected with the plasmids pGFP/Ub–MAGE-
31–314, pGFP/Ub–MAGE-3271–279, pGFP/Ub–MAGE-3256–279,
or pGFP/Ub–MAGE-3271–285 coding for the reference
GFPha–Ub and either MAGE-31–314, MAGE-3271–279, MAGE-
3256–279, or MAGE-3271–285, respectively (Fig. 1, constructs
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I–IV). The transfected cells were labeled with [35S]meth-
ionine/cysteine for 60 min, lysed, immunoprecipitated us-
ing saturating amounts of monoclonal anti-ha antibody and
monoclonal anti–MAGE-3 antibody, and analyzed by
SDS-PAGE and autoradiography. The radioactive band
corresponding to the reference GFPha–Ub could be de-
tected in all lanes where cells had been transfected with
UPR-based plasmids (Fig. 2, lanes a–d) but not in mock-
transfected cells (lane e). The protein MAGE-3 was only
detected in cells transfected with the full length MAGE-3
gene (lane a) and migrated as a doublet. The upper band of
the doublet is the result of a posttranslational modification
other than phosphorylation or N-glycosylation (data not
shown). The presence of the reference protein in the other
lanes confirmed the expression of the MAGE-3 protein
fragments. Using the GFP-based UPR technique, we esti-
mated that the transiently transfected constructs were ex-
pressed in z2% of the melanoma cells (data not shown).
CTL Recognition of Cells Expressing MAGE-31–314, MAGE-
3271–279, and MAGE-3271–279 Extended Precursors. NA8-MEL
cells transfected with pGFP/Ub–MAGE-31–314 (Fig. 1,
construct I) and pGFP/Ub–MAGE-3271–279 (construct II)
encoding the reference protein GFPha–Ub and either
MAGE-31–314 or MAGE-3271–279, respectively, were incu-
bated with cells from the CTL line specific for MAGE-
3271–279 at a lymphocyte-to-target cell ratio of 30:1. After
24 h of coculture, supernatants were assayed for the pres-
ence of TNF-a released by activated CTL. The amount of
TNF-a produced by CTL incubated with cells expressing
MAGE-31–314 was not significantly higher than that pro-
duced by CTL incubated with mock-transfected cells (Fig.
3). In contrast, cells expressing MAGE-3271–279 were effi-
ciently recognized by CTL as indicated by the 50-fold in-
crease in the amount of TNF-a produced. As expected,
addition of a saturating amount of the corresponding
MAGE-3271–279 synthetic peptide to mock-transfected cells
resulted in a strong production of TNF-a. Therefore, the
impaired presentation of MAGE-3271–279 by NA8-MEL
cells transfected with MAGE-31–314 was not caused by an
inefficient transport or loading of the peptide on HLA-
A*0201 molecules but rather by an inaccurate processing
of the protein MAGE-3.
To locate the region of the protein affecting the genera-
tion of the antigenic peptide, we extended the sequence of
MAGE-3271–279 at the NH2 terminus by 15 amino acids
(Fig. 1, construct III) and at the COOH terminus by 6
amino acids (construct IV). NA8-MEL cells were trans-
fected with the plasmids coding for GFPha–Ub and either
MAGE-3256–279 or MAGE-3271–285, respectively. Cells ex-
pressing the fragment MAGE-3256–279 were well recognized
by CTL (Fig. 3). On the contrary, cells transfected with the
plasmid encoding MAGE-3271–285 were not recognized by
CTL. The length of the COOH-terminal extension did
not influence the recognition of the transfected cells, as
cells expressing MAGE-3271–279 with a COOH-terminal
extension of 15 amino acids did not lead to a recognition of
the cells, either (data not shown). Therefore, the processing
protease was unable to generate the MAGE-3271–279 peptide
from a COOH-terminally extended precursor but could
generate it from a precursor containing a preprocessed
COOH terminus as the result of genetic engineering.
Analysis of Peptide Fragments Generated after Digestion with
Purified Proteasome In Vitro. The human proteasome has
been implicated in the generation of antigenic peptides
presented by HLA class I molecules to CTL (11–13). We
tested whether the peptide fragments obtained after expo-
sure of NH2- and COOH-terminally extended MAGE-
3271–279 precursors to purified human proteasome correlated
with the results obtained using transfected cells. Synthetic
peptide MAGE-3271–285 was incubated for 40 min at 378C
in the presence of proteasome purified from blood and was
subsequently analyzed by mass spectrometry (Fig. 1 B and
Fig. 4, A and B). A major peak corresponding to the origi-
nal peptide MAGE-3271–285 (theoretical mass 1,766 daltons)
was detectable at time 0. Several additional peaks of lower
mass appeared after incubation with the proteasome. These
Figure 2. The use of UPR
technique in assessing the ex-
pression of transfected plasmids.
NA8-MEL cells were transiently
transfected with plasmids pGFP/
Ub–MAGE-31–314 (lane a),
pGFP/Ub–MAGE-3271–279 (lane b), pGFP/Ub–MAGE-3256–279 (lane c),
pGFP/Ub–MAGE-3271–285 (lane d), or mock transfected (lane e). Trans-
fected cells were metabolically labeled with [35S]methionine/cysteine, fol-
lowed by immunoprecipitation and SDS-PAGE analysis. The band corre-
sponding to the reference GFPha–Ub is indicated on the left. In lane a,
the protein MAGE-31–314 detected by a monoclonal antibody raised
against MAGE-3 migrates as a doublet. The upper band of the doublet is
the result of a posttranslational modification. The band corresponding to
GFPha–Ub is absent in mock-transfected cells (lane e).
Figure 3. Recognition of transfected NA8-MEL cells by CTL specific
for HLA-A*0201–restricted MAGE-3271–279. Cells transfected with the
plasmids pGFP/Ub–MAGE-31–314, pGFP/Ub–MAGE-3271–279, pGFP/
Ub–MAGE-3256–279, and pGFP/Ub–MAGE-3271–285 were cocultured for
24 h with CTL at a lymphocyte to target cell ratio of 30:1. The produc-
tion of TNF-a was measured by testing the toxicity of the culture super-
natant on TNF-sensitive cells. The amount of TNF-a produced by cells
expressing MAGE-31–314 or MAGE-3271–285 corresponds to 4 pg/ml and is
not significantly different from mock-transfected cells (solid black bar).
Cells expressing MAGE-3271–279 or MAGE-3256–279 induced a 50-fold in-
crease in the production of TNF-a. NA8-MEL cells exposed to 1 mg/ml
exogenous MAGE-3271–279 peptide (white bar) were efficiently recog-
nized by the CTL.
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degradation products were unambiguously identified as
the 11-mer MAGE-3271–281 (1,288 daltons), the 10-mer
MAGE-3271–280 (1,187 daltons), the 8-mer MAGE-3271–278
(959 daltons) and the 7-mer MAGE-3272–278 (812 daltons).
No peak corresponding to the 9-mer MAGE-3271–279
(1,058 daltons) was detected.
A similar analysis was performed using peptide MAGE-
3256–279 (Fig. 1 B). The major peak detected at time 0 cor-
responded to the original peptide (2,767 daltons; Fig. 4 D).
After incubation with proteasome, the 9-mer correspond-
ing to MAGE-3271–279 (1,058 daltons) was clearly detected
(Fig. 4 E). Moreover, several other peaks were detected
and identified as the 10-mer MAGE-3256–265 (1,163 dal-
tons), the 8-mer MAGE-3272–279 (911 daltons), and the 7-mer
MAGE-3272–278 (812 daltons). The relative signal intensity
of peptide MAGE-3256–279 was reproducibly lower than
that of peptide MAGE-3271–285 and may reflect the chemi-
cal properties of this peptide. Thus, results obtained with in
vitro digestion of synthetic MAGE-3 peptide extensions
not only confirmed the results obtained with DNA-
encoded peptides expressed intracellularly but also enabled
precise identification of the degradation products.
Selective Inhibition of Proteasomal Activity In Vitro Influences
the Production of Peptide MAGE-3271–279. To ascertain the
role of the different enzymatic activities of the proteasome
in the generation of the proteolytic fragments in vitro, we
performed experiments similar to the one described above
in the presence of lactacystin, a specific inhibitor of the
proteasome. Lactacystin has been shown to irreversibly
block the trypsin-like and chymotrypsin-like activities, re-
versibly inhibit the PGPH activity, and moderately block
the BrAAP activity of the proteasome (28, 29).
Purified MAGE-3256–279 and MAGE-3271–285 peptides
were incubated for 40 min in the presence of proteasome
and 50 mM lactacystin and analyzed by mass spectrometry
(Fig. 4, C and F). Digestion of peptide MAGE-3271–285 (C)
resulted in the appearance of several peaks with masses sim-
ilar to those obtained after the digestion without lactacystin
(compare with B). Unexpectedly, the peptide species cor-
responding to the 9-mer MAGE-3271–279 (1,058 daltons)
was generated to a detectable level. The peak correspond-
ing to the 7-mer MAGE-3272–278 (812 daltons) was not de-
tectable in the sample incubated with the proteasome
inhibitor. Digestion of peptide MAGE-3256–279 in the pres-
ence of lactacystin (F) yielded new peaks corresponding to
the 12-mer MAGE-3256–267 (1,331 daltons) and the 6-mer
MAGE-3256–261 (807 daltons), in addition to the 9-mer
MAGE-3271–279 (1,058 daltons) and the 8-mer MAGE-3272–279
(912 daltons) already detected in digestion without lacta-
cystin (E). It is interesting to note that the relative intensity
of the peak corresponding to the antigenic 9-mer was re-
producibly higher in digestions containing lactacystin than
in those performed in the absence of lactacystin (compare E
and F).
Lactacystin Inhibits Two of the Three Tested Proteasomal Ac-
tivities. To identify the lactacystin-mediated effect on the
enzymatic activity of the proteasome, we performed a di-
gestion of the fluorescent substrates Z–GGR–bNA (for
trypsin-like activity), Z–LLE–bNA (for PGPH activity),
and Suc–LLVY–AMC (for chymotrypsin-like activity) in
Figure 4. Fragments generated
after digestion of synthetic pep-
tides with purified proteasome in
vitro. The synthetic peptide
MAGE-3271–285 (A–C) corre-
sponding to a COOH-terminal
extension of the antigenic peptide
MAGE-3271–279 or MAGE-3256–279
(D–F) corresponding to an NH2-
terminal extension of the anti-
genic peptide were incubated for
0 (A and D) or 40 min (B and E)
at 378C with 15 mg proteasome
purified from human blood. A
40-min digestion was also per-
formed in the presence of 50 mM
lactacystin (C and F). The samples
were then analyzed by mass spec-
trometry. The identity of the de-
tected peaks was determined
based on the specific mass of each
peptide fragment and is denoted
by the position of the fragment
within the precursor peptide se-
quence. Note the presence of a
peak corresponding to the anti-
genic peptide MAGE-3271–279 in
C, E, and F. The sequences of the
precursor peptides are indicated,
in one-letter code, at the top and
the antigenic 9-mer is under-
lined. Contaminating peaks are
not labeled.
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the presence or absence of 50 mM lactacystin (Fig. 5). Al-
though all fluorescent substrates were cleaved by the pro-
teasome in the absence of lactacystin as detected by in-
creased fluorescence, two of the three activities of the
proteasome could be efficiently blocked by the addition of
lactacystin. The PGPH activity was only marginally af-
fected by the presence of lactacystin. Further purification of
the proteasome by size chromatography did not alter this
effect, ruling out the contribution of other low molecular
weight proteases present in the purified preparation (data
not shown).
Specific CTL Can Recognize Target Cells Pulsed after Di-
gestion of Peptide Precursors. Since the generation of the
9-mer MAGE-3271–279 from peptides MAGE-3271–285 and
MAGE-3256–279 was enhanced in the presence of lactacys-
tin, we tested whether the peptide generated under this
condition was able to sensitize target cells for lysis by
MAGE-3271–279–specific CTL. Peptides MAGE-3271–285 and
MAGE-3256–279 were either added directly to target cells or
were first incubated with purified proteasome for 20 min at
378C in the absence or presence of lactacystin. After 20
min, the reaction was stopped by the addition of 5% TFA
and lyophilized. The lyophilized material was resuspended
in medium and added in different dilutions to 51Cr-labeled
T2 cells. These HLA-A*02011 cells are TAP deficient but
can be efficiently sensitized with exogenous peptides for
recognition by specific CTL.
Direct addition of the peptide MAGE-3271–285 resulted in
lysis of T2 cells only at very high peptide concentration
(Fig. 6 A). This activity was probably caused by the pres-
ence of a small amount of peptide MAGE-3271–280 pro-
duced by the hydrolysis of peptide MAGE-3271–285. Indeed,
the MAGE-3271–279–specific CTL used in the present study
was able to recognize the synthetic decapeptide MAGE-
3271–280 (50% maximal lysis at 100 nM), although much less
efficiently than the 9-mer MAGE-3271–279 (50% maximal
lysis at 0.1 nM). No additional activity was observed after
digestion of peptide MAGE-3271–285 with proteasome for
20 min (Fig. 6 A). In contrast, incubation of peptide
MAGE-3271–285 with proteasome and lactacystin for 20 min
resulted in the generation of an antigenic peptide recog-
nized z20-fold more efficiently by the MAGE-3271–279–
specific CTL (B). Based on the specificity of the CTL and
on the degradation products detected by mass spectrome-
try, we concluded that the antigenic peptide MAGE-
3271–279 was indeed produced in the presence of lactacystin.
Digestion of peptide MAGE-3271–285 with trypsin completely
abrogated recognition of the target cells by specific CTL.
Figure 5. Proteolytic activity of purified proteasome in the absence or
presence of proteasome inhibitors. The tryptic-like, PGPH, and chymo-
tryptic-like activities of purified proteasome (5 mg) were tested using 100
mM Z–GGR–bNA (black bar), 100 mM Z–LLE–bNA (hatched bar), or
10 mM Suc–LLVY–AMC (gray bar), respectively. In samples containing
the inhibitor lactacystin (50 mM), proteasome was incubated for 15 min at
258C before the addition of the fluorogenic peptide substrate. The reac-
tion was allowed to proceed for 20 min at 258C. Peptide hydrolysis was
detected by monitoring the increased fluorescence in arbitrary units
(A.U.) emitted by the released fluorogenic group bNA (excitation/emis-
sion of 335:410 nm) or AMC (excitation/emission of 380:440 nm). In
the absence of proteasome (2), only background activity is detected. A
representative plot is depicted here. Identical results were obtained using
three independent proteasome preparations and two different lots of lacta-
cystin.
Figure 6. Lysis of T2 target cells pulsed with proteasome-digested pep-
tide products by MAGE-3271–279–specific CTL. Precursors corresponding
to MAGE-3271–285 (A and B) or MAGE-3256–279 (C and D) were incu-
bated with proteasome for 0 or 20 min at 378C in the absence (A and C)
or presence (B and D) of 50 mM lactacystin. In each condition, the pre-
cursor was also digested with trypsin or maintained in the absence of pro-
teasome. Upon completion of the incubation, the samples were lyoph-
ilized, resuspended in medium, and added in fivefold dilution steps to
51Cr-labeled T2 cells. Cr release was measured after 4 h. The half-maxi-
mal lysis of cells pulsed with a saturating amount of the antigenic MAGE-
3271–279 peptide was 0.01 nM (not shown).
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A similar assay was performed using peptide MAGE-
3256–279 as substrate. Again, direct addition of the peptide
precursor produced low but detectable lytic activity at high
concentration. Digestion of the extended peptide for 20
min in the absence of lactacystin led to a 10-fold increase in
lytic activity (Fig. 6 C), an effect compatible with the de-
tection of peptide MAGE-3271–279 in the digestion products
analyzed by mass spectrometry (Fig. 4 E). This activity was
completely abolished by the addition of trypsin. However,
digestion of peptide MAGE-3256–279 in the presence of 50 mM
lactacystin resulted in 100-fold–increased recognition (Fig.
6 D). This effect was most likely caused by the increased
amount of MAGE-3271–279 generated after proteasomal di-
gestion in the presence of lactacystin as suggested by the in-
creased relative intensity of the MAGE-3271–279 peak de-
tected by mass spectrometry (Fig. 4 F).
Treatment of Cells Expressing MAGE-31–314 with Proteasome
Inhibitors Results in Efficient Presentation of MAGE-3271–279.
To ascertain the relevance of the positive effect of lactacys-
tin on the generation of peptide MAGE-3271–279 by the
proteasome, we infected HLA-A*02011 lymphoblastoid
cells with rec. v.v. coding for MAGE-31–314 (Fig. 7 A). In-
fected cells expressing the full length protein MAGE-31–314
were not efficiently recognized by MAGE-3271–279–specific
CTL. However, treatment of the same cells with lactacys-
tin prior to and during the infection lead to the efficient ly-
sis of the infected cells. To determine whether the lactacys-
tin-mediated effect observed in lymphoblastoid cells upon
infection and high level expression of MAGE-3 could also
be observed in uninfected melanoma cells, lysis of HLA-
A*02011MAGE-31 melanoma cells was measured after
treatment with lactacystin. As expected, lysis of untreated
target cells was very low (Fig. 7 B). In contrast, treatment
with lactacystin led to efficient lysis of the melanoma cells.
A similar effect was also observed after treatment of the tar-
get cells with the calpain (and proteasome) inhibitor I
LLnL. Taken together, these results strongly support the
findings obtained after in vitro digestion of peptide precur-
sors by purified proteasome and lead us to conclude that
the generation and presentation of peptide MAGE-3271–279
detected after treatment with lactacystin is a direct conse-
quence of the partial inhibition of the proteasome in cells.
Discussion
Two major findings are reported in this work: First, mel-
anoma cells transfected with cDNA encoding either the
preprocessed antigenic peptide MAGE-3271–279 (FLWG-
PRALV) or the same peptide with an NH2-terminal exten-
sion were recognized by MAGE-3271–279–specific CTL. In
contrast, melanoma cells expressing the full length protein
MAGE-31–314 or peptide MAGE-3271–279 with a COOH-
terminal extension were not recognized. This discrepancy
stems from the inappropriate proteasomal cleavage at the
COOH terminus of the antigenic peptide. Second, treat-
ment of MAGE-31 melanoma cells with lactacystin re-
sulted in the recognition of these normally unrecognized
cells by MAGE-3271–279–specific CTL. This effect strongly
correlates with the partial inhibition of proteasomal activity
in vitro and the lactacystin-induced generation of peptide
MAGE-3271–279 from the COOH-terminally extended pre-
cursor.
Expression of a minigene product in transfected cells has
been difficult to assess by means other than functional as-
says. However, use of the UPR technique in this study not
only allowed us to confirm the presence of the various
minigene products via the detection of the reference pro-
tein GFP–Ub but also to quantitate the various MAGE-3
gene products, as both the reference protein GFP–Ub and
the MAGE-3 protein, or protein fragments, were produced
in equimolar amounts. Thus, the observed differences in
CTL recognition of target cells transfected with the mini-
gene encoding peptide MAGE-3271–279 or the full length
protein MAGE-31–314 could not be attributed to different
expression levels of the two products but rather to the gen-
eration, or lack thereof, of the antigenic peptide. Cells ex-
pressing a short-lived variant of the MAGE-31–314 protein
were not recognized by specific CTL, either (data not
shown), eliminating the possibility that the lack of recogni-
tion was caused by a slow degradation of the MAGE-3
Figure 7. (A) Lactacystin restores the presen-
tation of the MAGE-3271–279 in cells expressing
virally encoded MAGE-3. When left untreated,
the HLA-A*02011MAGE-32 lymphoblastoid
cell line LCL721.45 infected with rec. v.v. en-
coding MAGE-3 is not recognized by MAGE-
3271–279–specific CTL (rec. v.v.-MAGE3).
Treatment of the infected cells with lactacystin
prior to and during the infection renders them
sensitive to the lysis by specific CTL (rec.
v.v.-MAGE3 1 lactacystin). (B) Effect of pro-
teasome inhibitors on the presentation of pep-
tide MAGE-3271–279 in human melanoma cells.
In contrast to the untreated HLA-A*02011
MAGE-31 melanoma cell line SK23-MEL,
treatment with either 10 mM lactacystin or 100
mM LLnL for 17 h enhances the presentation of
peptide MAGE-3271–279 to specific CTL. See
Materials and Methods for details.
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protein leading to a suboptimal concentration of the anti-
genic peptide. Finally, reciprocal transplantation of the
MAGE-3271–279 sequence into unrelated proteins indicated
that the impaired generation of the antigenic peptide was
not caused by residues flanking peptide MAGE-3271–279
(data not shown). Altogether, these results suggested that
the sequence of peptide MAGE-3271–279 itself contributed
to the improper processing of the MAGE-3 protein and led
us to study the role of the proteasome in the deficient pro-
duction of the antigenic peptide.
The involvement of the proteasome in the processing of
antigenic peptides has been inferred from two sets of data:
First, treatment of target cells with specific proteasome in-
hibitors abolished CTL-mediated recognition of antigenic
peptides derived from intracellular proteins without affect-
ing recognition of preprocessed endogenous or exogenous
antigenic peptides (13). Second, analysis of proteasome-
mediated degradation of synthetic peptide substrates in vitro
revealed that the structural features of the digested products
were compatible with those of peptides naturally associated
with MHC class I molecules (30). However, several reports
have recently demonstrated that the presentation of certain
antigenic peptides, derived mostly from protein fragments,
were insensitive to the effects of proteasome inhibitors (28,
31, 32). Moreover, cell surface expression of assembled
MHC class I proteins in cells lacking proteasomal function
suggests that other proteases may be involved in the genera-
tion of antigenic peptides (33). Therefore, the participation
of two complementary and possibly overlapping proteolytic
systems in antigen processing could be envisaged and would
be compatible with our results obtained after treatment of
melanoma cells with lactacystin. To address this question in
greater detail, we isolated human proteasome and per-
formed in vitro digestion studies using synthetic peptides.
After digestion, the samples were immediately analyzed by
mass spectrometry so as to uncover all possible fragments
generated by the proteasome. Using this approach, we ob-
tained strong evidence in favor of the involvement of the
proteasome in the final proteolytic step leading to the gen-
eration of the antigenic peptide MAGE-3271–279, notwith-
standing the possibility that distinct cellular proteases may be
involved at other stages in the processing of the MAGE-3
protein into precursor peptide fragments.
Five proteolytic activities of the proteasome have been
described using short synthetic fluorogenic peptides: a tryp-
tic-like activity, a chymotryptic-like activity, a PGPH ac-
tivity, a BrAAP activity, and a SNAAP activity (3). Lacta-
cystin has been shown to irreversibly block the trypsin-like
and chymotrypsin-like activities and only partially block
the PGPH and the BrAAP activities (28, 29, 34). No infor-
mation is available on the inhibition of the SNAAP activity
by lactacystin. In agreement with these results, we also
found that the proteasome inhibitor lactacystin did not
completely abrogate certain proteasomal activities but re-
sulted in an altered degradation of synthetic peptides. Al-
though previous results indicated that I LLnL blocks all five
activities, recent reports have shown only selective inhibi-
tion of the chymotryptic-like activity (10, 13, 34).
In the presence of lactacystin, the degradation of
MAGE-3 peptide precursors by purified proteasome was
only partially and selectively inhibited, even if the tryptic
and chymotryptic activities on short fluorogenic peptides
were completely abrogated (Figs. 4 and 5). Indeed, we
could still detect fragments generated by cleavage after leu-
cine, valine, glutamic acid, alanine, and threonine. There-
fore, we envisage two possibilities: First, the remaining
PGPH activity not only cleaves at the COOH terminus of
glutamic acid but may be more permissive and also cleave
after nonacidic amino acid residues, or, second, the cata-
lytic subunits responsible for the BrAAP and SNAAP activ-
ities of the proteasome, in addition to those responsible for
the PGPH activity, are not affected by lactacystin. In light
of recent results obtained after the analysis of peptide frag-
ments generated by purified yeast proteasome (34), we fa-
vor the first hypothesis and suggest that the functionally de-
fined PGPH activity is mediated by the same catalytic
subunit as are the SNAAP and/or BrAAP activities. It is
noteworthy that, in some cases, the PGPH activity of
mammalian proteasome has been shown to result in cleav-
age after aromatic amino acids (35).
Close comparison of the fragments detected by mass
spectrometry in the absence or presence of lactacystin sug-
gests that, in the case of peptide MAGE-3271–285, the anti-
genic fragment MAGE-3271–279 is only detected in the ab-
sence of the fragment MAGE-3272–278. The production of
the latter appears to be inhibited by lactacystin. Assuming
the presence of two competing proteolytic activities of the
proteasome, one dominant under normal conditions and
producing peptide MAGE-3272–278 and the other resulting
in peptide MAGE-3271–279, it is possible that the inhibition
of the dominant activity by lactacystin favors the lactacys-
tin-insensitive activity, yielding only the antigenic peptide
MAGE-3271–279. Alternatively, the positioning of the pep-
tide in the inner cavity of the proteasome may favor the
cleavage, generating peptide MAGE-3272–278 under normal
conditions. The covalent binding of lactacystin to the sub-
unit responsible for the chymotryptic activity (29) may re-
orient the peptide substrate in the cavity and lead to the
generation of peptide MAGE-3271–279.
It has been reported that antigenic peptides from the
same protein may be processed with different efficiencies
(36, 37). In this context, it is noteworthy that the protein
MAGE-3 contains, in addition to the poorly presented
peptide studied here, other antigenic peptides which are
well presented by MAGE-31 melanoma cells in association
with HLA-A1 or HLA-B44 molecules (15, 16). In a survey
of antigenic peptides carrying the motif Ala–Leu–Val
present at the COOH terminus of peptide MAGE-3271–279,
we identified two such peptides. The first one, derived from
the influenza nucleoprotein NP147–155 (H-2 Kd–restricted),
has been shown to be inefficiently produced in H-2 Kd–posi-
tive infected cells (z30 peptides/cell) in comparison to an-
other antigenic peptide NP50–57 (1,800 peptides/cell; 36).
Interestingly, recent results have indicated that the presen-
tation of peptide NP147–155 in infected cells was enhanced
by the addition of lactacystin (38). Although it has been
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shown that amino acids at position 156 could positively in-
fluence the generation of the antigenic peptide NP147–155
(39), we did not observe any effect of the amino acid at the
COOH terminus of the cleavage site of peptide MAGE-
3271–279. Indeed, transplantation of the MAGE-3271–279
sequence into two unrelated proteins (carrying either the
residue histidine or isoleucine immediately after the COOH-
terminal valine) did not result in the presentation of pep-
tide MAGE-3271–279 (data not shown). The second peptide
is derived from the melanosomal TRP-2 protein (TRP-
2476-484, HLA-A*0201-restricted). Preliminary results sug-
gest that this peptide is not presented by cells expressing
TRP-2 but is efficiently presented when expressed as a
minigene (Noppen, C., G. Spagnoli, and F. Lévy, unpub-
lished results). All of these observations can be explained by
the presence of unfavorable amino acids surrounding the
cleavage site and acting as “negative processing signals.”
Elucidation of the exact nature of the postulated negative
processing signal and determination of other putative sig-
nals is underway and should further refine the current pre-
diction algorithms used to select potential antigenic pep-
tides. More importantly, understanding the proteolytic
machinery controlling the generation and presentation of
tumor-specific antigenic peptides in tumor cells should fa-
cilitate the development of efficient peptide-based vaccines
aimed at inducing or enhancing the generation of tumor-
reactive CTL in cancer patients. In parallel, demonstration
that proteasome inhibitors like lactacystin or LLnL lead to
the recognition of a peptide tumor antigen by specific CTL
in melanoma cells opens the way to the development of
specific proteasome inhibitors able to induce the presenta-
tion of antigens recognized by CTL and, hence, broaden
the spectrum of CTL-defined tumor antigenic peptides to
be considered for cancer vaccines. In this respect, the re-
cent demonstration that the drug ritonavir, originally de-
scribed as an inhibitor of HIV-1 protease and administered
to HIV-1–infected patients, can act as proteasome inhibitor
suggests that this drug may also favor the generation of new
peptide tumor antigens efficiently recognized by specific
CTL (40).
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